Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.

Brain tumor pathology - 1 Oct 2015

Ikota Hayato, Nobusawa Sumihito, Arai Hideo, Kato Yukinari, Ishizawa Keisuke, Hirose Takanori, Yokoo Hideaki

Abstract excerpt

Glioma cells with the isocitrate dehydrogenase (IDH) 1 G395A mutation are strongly immunopositive for mIDH1(R132H), an antibody against mutant IDH1(R132H) (clone H09). However, we encountered some gliomas which were ambiguously positive for mIDH1(R132H) despite having the IDH1 G395A mutation. The aim of this study was to establish an evaluation procedure of IDH1 status by immunohistochemistry. Forty-three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression

Share to Gene Expression Regulation, Neoplastic

Share to Glioma

Share to Immunohistochemistry

Share to Isocitrate Dehydrogenase

Share to Young Adult

Source

Identifiers

PMID: 26006098
DOI: 10.1007/s10014-015-0222-8

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.PMID 26006098Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.Semantic proximity Read ↗

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.Semantic proximity Read ↗

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.Semantic proximity Read ↗

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.Semantic proximity Read ↗

Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.Semantic proximity Read ↗

IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.Semantic proximity Read ↗

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.Semantic proximity Read ↗

Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.Semantic proximity Read ↗

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.Semantic proximity Read ↗

Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.Semantic proximity Read ↗

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.